C5 and paroxysmal nocturnal hemoglobinuria: A complement-targeted therapy, eculizmab which is an anti-C5 antibody developed to prevent C-activation related anemia in patients with PNH and improve survival [146], has recently been used to treat aHUS associated with C dysregulation [147].